Acceleron Pharma (XLRN) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma (XLRN) PT Raised to $46 at RBC Capital
February 28, 2018 7:44 AM ESTRBC Capital raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $46.00 (from $44.00) while maintaining a Sector Perform rating.
... MoreAcceleron Pharma (XLRN) PT Raised to $65 at Ladenburg Thalmann
February 28, 2018 6:45 AM ESTLadenburg Thalmann raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $65.00 (from $54.00) while maintaining a Buy rating.
Analyst Geoffrey Porges remains positive on the company noting Luspatercept is progressing and muscle programs offer upside over the LT.
... MoreJPMorgan Upgrades Acceleron Pharma (XLRN) to Overweight
February 26, 2018 4:27 AM ESTJPMorgan upgraded Acceleron Pharma (NASDAQ: XLRN) from Neutral to Overweight with a price target of $52.00 (from $33.00).
Analyst Eric Joseph sees upside in the company's pivotal mid-year Luspatercept datasets. The analyst believes there are multiple levers for upside in the model due to... More
